FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
Pirtobrutinib shows activity in relapsed and refractory marginal zone lymphoma patients in a Phase 1/2 trial
Early trial shows pirtobrutinib helped some patients with relapsed marginal zone lymphoma
This Phase 1/2 trial evaluated pirtobrutinib in 36 patients with relapsed and refractory marginal zone lymphoma.
A new drug helped more than half of patients with relapsed lymphoma shrink their tumors, offering hope for those who have run out of other t…